Blood test may predict liver cancer treatment response
NCT ID NCT07303712
First seen Jan 03, 2026 · Last updated May 13, 2026 · Updated 24 times
Summary
This study is testing whether a blood test (liquid biopsy) can predict how well liver cancer responds to a targeted radiation treatment called Y90 radioembolization. Researchers will take blood samples from 12 adults with liver cancer before and after treatment to look for cancer cells and DNA. The goal is to see if early changes in these blood markers can forecast treatment success, potentially leading to better personalized care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
VA Palo Alto Health Care System
RECRUITINGPalo Alto, California, 94304, United States
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.